{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:11:49Z","timestamp":1760544709721,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009250","name":"National Institute for Social Care and Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009250","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Academic Health Science Collaboration"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.clon.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T18:11:21Z","timestamp":1521655881000},"page":"409-417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Prospective Phase I\/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3)"],"prefix":"10.1016","volume":"30","author":[{"given":"S.","family":"Gollins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Massalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mullard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Garcia-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Cancer Research UK","key":"10.1016\/j.clon.2018.03.002_bib1"},{"key":"10.1016\/j.clon.2018.03.002_bib2","unstructured":"National oesophago-gastric cancer audit 2016. Available at: http:\/\/www.hqip.org.uk\/resources\/national-oesophago-gastric-cancer-audit-2016\/. [Accessed September 2016]."},{"key":"10.1016\/j.clon.2018.03.002_bib3","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et\u00a0al, editors. SEER cancer statistics review, 1975-2010. Bethesda, MD: National Cancer Institute. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2010\/(based on November 2012 SEER data submission, posted to the SEER web site 2013). [Accessed October 2013]."},{"key":"10.1016\/j.clon.2018.03.002_bib4","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.03.002_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/oxfordjournals.annonc.a057858","article-title":"Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial","volume":"2","author":"Lacave","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2018.03.002_bib6","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5","article-title":"A\u00a0phase III randomised study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer","volume":"71","author":"Kim","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2018.03.002_bib7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0959-8049(94)90170-8","article-title":"Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis","volume":"30","author":"Rougier","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2018.03.002_bib8","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","volume":"18","author":"Vanhoefer","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.03.002_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2003.04.130","article-title":"Randomised phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205)","volume":"21","author":"Ohtsu","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2018.03.002_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2018.03.002_bib11","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III Study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.clon.2018.03.002_bib12","article-title":"COUGAR-02: a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma (abstract)","volume":"31","author":"Cook","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.03.002_bib13","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00280-010-1444-4","article-title":"Phase I\/II study of a combination of docetaxel, capecitabine and cisplatin (DXP) as first line chemotherapy in patients with advanced gastric cancer","volume":"67","author":"Kang","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"10.1016\/j.clon.2018.03.002_bib14","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.7314\/APJCP.2014.15.20.8661","article-title":"Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer","volume":"15","author":"Bilici","year":"2014","journal-title":"Asian Pac J Cancer"},{"issue":"3","key":"10.1016\/j.clon.2018.03.002_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"author":"CTCAE","key":"10.1016\/j.clon.2018.03.002_bib16"},{"issue":"2; Suppl. 4","key":"10.1016\/j.clon.2018.03.002_bib17","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1053\/j.seminoncol.2005.04.005","article-title":"Docetaxel in the treatment of esophageal cancer","volume":"32","author":"Rigas","year":"2005","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2018.03.002_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.clon.2018.03.002_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO clinical practise guidelines","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2018.03.002_bib20","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2006.08.0135","volume":"25","author":"Roth","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2018.03.002_bib21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00280-009-1171-x","article-title":"Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer","volume":"66","author":"Sym","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.clon.2018.03.002_bib22","first-page":"4151","article-title":"Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. A phase II study","volume":"32","author":"Polyzos","year":"2012","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.clon.2018.03.002_bib23","first-page":"1403","article-title":"Osaka Gastrointestinal Cancer Chemotherapy Study Group. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403)","volume":"32","author":"Tamura","year":"2012","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.clon.2018.03.002_bib24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a058932","article-title":"A\u00a0phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)","volume":"5","author":"Findlay","year":"1994","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clon.2018.03.002_bib25","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/1097-0142(19951115)76:10<1694::AID-CNCR2820761004>3.0.CO;2-K","article-title":"Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report","volume":"76","author":"Zaniboni","year":"1995","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clon.2018.03.002_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/07357900600633924","article-title":"A\u00a0phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus","volume":"24","author":"Kulke","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clon.2018.03.002_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5301\/tj.5000556","article-title":"Safety and efficacy of dose-dense chemotherapy with TCF regimen in elderly patients with locally advanced or metastatic gastric cancer","volume":"103","author":"Liguigli","year":"2017","journal-title":"Tumori"},{"issue":"Suppl.","key":"10.1016\/j.clon.2018.03.002_bib28","volume":"35","author":"Al-Batran","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"9911","key":"10.1016\/j.clon.2018.03.002_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clon.2018.03.002_bib30","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518301626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518301626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:44:35Z","timestamp":1760543075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655518301626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0936655518301626"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2018.03.002","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Phase I\/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3)","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}